drugset / Trial / NCT00079586

Comparing Angiomax to Heparin With Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)

NCT00079586

Phase 3 Completed 150 enrolled The Medicines Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to demonstrate that in patients undergoing coronary artery bypass grafting (CABG) or CABG-Valve, or Isolated Cardiac Valve surgery on CPB (cardiac surgery), Angiomax is a safe and effective alternative anticoagulant to heparin with protamine reversal.

Timeline

Start
2004-04
Primary completion
Completion
2004-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Bivalirudin Peptide 2.5 mg/kg Intravenous
Comparator Heparin Other / unclassified